# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $10...
Citigroup analyst David Hoang maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $127 t...
Baird analyst Joel Beatty maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and raises the price target from $10...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $19...
Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(1.44) per share which missed the analyst consensus estimate of...
Morgan Stanley analyst Vikram Purohit upgrades Axsome Therapeutics (NASDAQ:AXSM) from Equal-Weight to Overweight and raises ...
Cantor Fitzgerald analyst Charles Duncan reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and maintains $107 p...